课题基金 / 基金详情

项目摘要

项目成果

Gurjit K. Khurana Hershey的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Allergic disorders are a major global health concern affecting 150 million people worldwide. Recently, epithelial cells have emerged as central participants in the pathogenesis of allergic inflammation. Defining the key epithelial drivers of the development, persistence, and progression of allergic inflammation is the focus of this application. Although epithelial cells are increasingly recognized as critical participants in the initiation and propagation of allergic inflammation, therapies that specifically target the epithelium are lacking. There are substantial gaps in understanding the mechanisms by which epithelial pathways converge to promote allergic inflammation that must be filled before interventions can be designed. Our U19 AADCRC proposal is designed to help fill this critical knowledge gap. We are uniquely poised for the proposed studies because of resources and collaborations that we have developed over the past 2 decades. Through the synergistic projects, we will explore the immunological mechanisms, which underpin initiation, persistence, and progression of allergic disease and provide novel insights into a key unanswered question in the allergy field: Why is allergic inflammation restricted to one tissue in some cases, while it progresses to involve additional tissues in other individuals? The projects are: Project 1 – To elucidate endotypes of AD that are predictive of progression to asthma and dissect the mechanistic basis of the contribution of epithelial kinesin family member 3A (KIF3A) to allergic inflammation and disease persistence/progression. Project 2 – To determine how protease/protease inhibitor imbalance promotes allergic inflammation - dissect the mechanistic basis by which the epithelial-derived protease inhibitor serine protease inhibitor Kazal-type 7 (SPINK7) promotes allergic inflammation . Project 3 – To dissect the mechanisms by which a newly described population of mucosal mast cells (MMC9) that make large amounts of IL-9, IL-13, and mast cell protease 1 (MCPt-1) develops and amplifies allergic inflammation to promote progression of AD to allergic asthma. Investigations in this domain will ultimately provide a road map for primary or secondary prevention of allergic disease. As such, this proposal is highly aligned with the stated programmatic priorities in the RFA-AI-15-032.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Medical Scientist Training Program
  • 批准号:
    10620999
  • 项目类别:
  • 资助金额:
    $92.89万
  • 财政年份:
    2023
  • 负责人:
    Gurjit K. Khurana Hershey
  • 依托单位:
Multi-omics of the Frequent Exacerbator Asthmatic
  • 批准号:
    10197294
  • 项目类别:
  • 资助金额:
    $45.2万
  • 财政年份:
    2021
  • 负责人:
    Gurjit K. Khurana Hershey
  • 依托单位:
Multi-omics of the Frequent Exacerbator Asthmatic
  • 批准号:
    10596089
  • 项目类别:
  • 资助金额:
    $45.2万
  • 财政年份:
    2021
  • 负责人:
    Gurjit K. Khurana Hershey
  • 依托单位:
Multi-omics of the Frequent Exacerbator Asthmatic
  • 批准号:
    10390405
  • 项目类别:
  • 资助金额:
    $45.2万
  • 财政年份:
    2021
  • 负责人:
    Gurjit K. Khurana Hershey
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: